Corcept Therapeutics. has filed a patent for a method to treat GR+ neuroepithelial tumors using selective glucocorticoid receptor modulators (SGRM) like mifepristone. The treatment involves administering non-steroidal SGRA to reduce tumor load in subjects with specific neuroepithelial tumors. GlobalData’s report on Corcept Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Corcept Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Corcept Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Corcept Therapeutics's grant share as of January 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.

A recently filed patent (Publication Number: US20240009194A1) discloses a method for treating neuroepithelial tumors that express the glucocorticoid receptor (GR+) in a subject. The method involves administering a non-steroidal selective glucocorticoid receptor antagonist (SGRA) in an effective amount to reduce the tumor load of the GR+ neuroepithelial tumor. The tumors eligible for treatment include schwannoma, ependymoma, or neurofibromatosis type 2 (NF 2) neuroepithelial tumors. The SGRA can be a cyclohexyl pyrimidine compound or a fused azadecalin compound, among others. The method may involve administering the SGRA for at least two weeks at a daily dose ranging from 1 to 100 mg/kg/day, either alone or in combination with other therapies like chemotherapy or radiation.

Furthermore, the patent claims encompass variations in the administration of the nonsteroidal SGRA, allowing for flexibility in treatment duration ranging from 1 to 80 weeks. The dosage of the SGRA can be adjusted within the specified range to tailor the treatment to individual patients. The method aims to effectively reduce the tumor load of neuroepithelial tumors, including schwannoma, ependymoma, or NF 2 neuroepithelial tumors. By targeting the glucocorticoid receptor expressed in these tumors, the non-steroidal SGRA offers a potential therapeutic approach for patients with these specific types of neuroepithelial tumors. The patent provides a detailed framework for the administration of the SGRA, emphasizing the importance of reducing the tumor load in patients suffering from GR+ neuroepithelial tumors.

To know more about GlobalData’s detailed insights on Corcept Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies